AustralieFrV1, PubMed, Curation, bibRecord, 001422

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Identifieur interne : 001422 ( PubMed/Curation ); précédent : 001421; suivant : 001423

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Auteurs : Miriam Krischke [Allemagne] ; Georg Hempel [Allemagne] ; Swantje Völler [Allemagne] ; Nicolas André [France] ; Maurizio D'Incalci [Italie] ; Gianni Bisogno [Italie] ; Wolfgang Köpcke [Allemagne] ; Matthias Borowski [Allemagne] ; Ralf Herold [Royaume-Uni] ; Alan V. Boddy [Royaume-Uni] ; Joachim Boos [Allemagne]

Source :

Cancer chemotherapy and pharmacology [ 1432-0843 ] ; 2016.

RBID : pubmed:27770238

Descripteurs français

KwdFr :
- Adolescent, Antibiotiques antinéoplasiques (pharmacocinétique), Coeur (), Doxorubicine (effets indésirables), Doxorubicine (pharmacocinétique), Doxorubicine (pharmacologie), Enfant, Enfant d'âge préscolaire, Femelle, Humains, Mâle, Nourrisson, Polymorphisme génétique, Troponine (sang), Tumeurs (traitement médicamenteux).
MESH :
- effets indésirables : Doxorubicine.
- pharmacocinétique : Antibiotiques antinéoplasiques, Doxorubicine.
- pharmacologie : Doxorubicine.
- sang : Troponine.
- traitement médicamenteux : Tumeurs.
- Adolescent, Coeur, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Mâle, Nourrisson, Polymorphisme génétique.

English descriptors

KwdEn :
- Adolescent, Antibiotics, Antineoplastic (pharmacokinetics), Child, Child, Preschool, Doxorubicin (adverse effects), Doxorubicin (pharmacokinetics), Doxorubicin (pharmacology), Female, Heart (drug effects), Humans, Infant, Male, Neoplasms (drug therapy), Polymorphism, Genetic, Troponin (blood).
MESH :
- chemical , adverse effects : Doxorubicin.
- chemical , blood : Troponin.
- chemical , pharmacokinetics : Antibiotics, Antineoplastic, Doxorubicin.
- chemical , pharmacology : Doxorubicin.
- drug effects : Heart.
- drug therapy : Neoplasms.
- Adolescent, Child, Child, Preschool, Female, Humans, Infant, Male, Polymorphism, Genetic.

Abstract

Doxorubicin is a key component in many pediatric oncology treatment regimens; still pharmacology data on which current dosing regimens are based are very limited.

DOI: 10.1007/s00280-016-3174-8
PubMed: 27770238

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001444

Links to Exploration step

pubmed:27770238

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.</title>
<author><name sortKey="Krischke, Miriam" sort="Krischke, Miriam" uniqKey="Krischke M" first="Miriam" last="Krischke">Miriam Krischke</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hempel, Georg" sort="Hempel, Georg" uniqKey="Hempel G" first="Georg" last="Hempel">Georg Hempel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Voller, Swantje" sort="Voller, Swantje" uniqKey="Voller S" first="Swantje" last="Völler">Swantje Völler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="André">Nicolas André</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="D Incalci, Maurizio" sort="D Incalci, Maurizio" uniqKey="D Incalci M" first="Maurizio" last="D'Incalci">Maurizio D'Incalci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bisogno, Gianni" sort="Bisogno, Gianni" uniqKey="Bisogno G" first="Gianni" last="Bisogno">Gianni Bisogno</name>
<affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Pediatria, Clinica di Oncoematologia, via Giustiniani, 3, 35100, Padua, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dipartimento di Pediatria, Clinica di Oncoematologia, via Giustiniani, 3, 35100, Padua</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kopcke, Wolfgang" sort="Kopcke, Wolfgang" uniqKey="Kopcke W" first="Wolfgang" last="Köpcke">Wolfgang Köpcke</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Borowski, Matthias" sort="Borowski, Matthias" uniqKey="Borowski M" first="Matthias" last="Borowski">Matthias Borowski</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Herold, Ralf" sort="Herold, Ralf" uniqKey="Herold R" first="Ralf" last="Herold">Ralf Herold</name>
<affiliation wicri:level="1"><nlm:affiliation>European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London, E14 5EU, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London, E14 5EU</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Boddy, Alan V" sort="Boddy, Alan V" uniqKey="Boddy A" first="Alan V" last="Boddy">Alan V. Boddy</name>
<affiliation wicri:level="1"><nlm:affiliation>Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Boos, Joachim" sort="Boos, Joachim" uniqKey="Boos J" first="Joachim" last="Boos">Joachim Boos</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. boosj@uni-muenster.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27770238</idno>
<idno type="pmid">27770238</idno>
<idno type="doi">10.1007/s00280-016-3174-8</idno>
<idno type="wicri:Area/PubMed/Corpus">001444</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001444</idno>
<idno type="wicri:Area/PubMed/Curation">001422</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001422</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.</title>
<author><name sortKey="Krischke, Miriam" sort="Krischke, Miriam" uniqKey="Krischke M" first="Miriam" last="Krischke">Miriam Krischke</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hempel, Georg" sort="Hempel, Georg" uniqKey="Hempel G" first="Georg" last="Hempel">Georg Hempel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Voller, Swantje" sort="Voller, Swantje" uniqKey="Voller S" first="Swantje" last="Völler">Swantje Völler</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Andre, Nicolas" sort="Andre, Nicolas" uniqKey="Andre N" first="Nicolas" last="André">Nicolas André</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="D Incalci, Maurizio" sort="D Incalci, Maurizio" uniqKey="D Incalci M" first="Maurizio" last="D'Incalci">Maurizio D'Incalci</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bisogno, Gianni" sort="Bisogno, Gianni" uniqKey="Bisogno G" first="Gianni" last="Bisogno">Gianni Bisogno</name>
<affiliation wicri:level="1"><nlm:affiliation>Dipartimento di Pediatria, Clinica di Oncoematologia, via Giustiniani, 3, 35100, Padua, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Dipartimento di Pediatria, Clinica di Oncoematologia, via Giustiniani, 3, 35100, Padua</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kopcke, Wolfgang" sort="Kopcke, Wolfgang" uniqKey="Kopcke W" first="Wolfgang" last="Köpcke">Wolfgang Köpcke</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Borowski, Matthias" sort="Borowski, Matthias" uniqKey="Borowski M" first="Matthias" last="Borowski">Matthias Borowski</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Herold, Ralf" sort="Herold, Ralf" uniqKey="Herold R" first="Ralf" last="Herold">Ralf Herold</name>
<affiliation wicri:level="1"><nlm:affiliation>European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London, E14 5EU, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London, E14 5EU</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Boddy, Alan V" sort="Boddy, Alan V" uniqKey="Boddy A" first="Alan V" last="Boddy">Alan V. Boddy</name>
<affiliation wicri:level="1"><nlm:affiliation>Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Boos, Joachim" sort="Boos, Joachim" uniqKey="Boos J" first="Joachim" last="Boos">Joachim Boos</name>
<affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. boosj@uni-muenster.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer chemotherapy and pharmacology</title>
<idno type="eISSN">1432-0843</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Antibiotics, Antineoplastic (pharmacokinetics)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Doxorubicin (adverse effects)</term>
<term>Doxorubicin (pharmacokinetics)</term>
<term>Doxorubicin (pharmacology)</term>
<term>Female</term>
<term>Heart (drug effects)</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Neoplasms (drug therapy)</term>
<term>Polymorphism, Genetic</term>
<term>Troponin (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Antibiotiques antinéoplasiques (pharmacocinétique)</term>
<term>Coeur ()</term>
<term>Doxorubicine (effets indésirables)</term>
<term>Doxorubicine (pharmacocinétique)</term>
<term>Doxorubicine (pharmacologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Polymorphisme génétique</term>
<term>Troponine (sang)</term>
<term>Tumeurs (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Doxorubicin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Troponin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibiotics, Antineoplastic</term>
<term>Doxorubicin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Doxorubicin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Heart</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Doxorubicine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Antibiotiques antinéoplasiques</term>
<term>Doxorubicine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Doxorubicine</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Troponine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Polymorphism, Genetic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Coeur</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Polymorphisme génétique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Doxorubicin is a key component in many pediatric oncology treatment regimens; still pharmacology data on which current dosing regimens are based are very limited.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27770238</PMID>
<DateCreated><Year>2016</Year>
<Month>10</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>06</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>06</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0843</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>78</Volume>
<Issue>6</Issue>
<PubDate><Year>2016</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Cancer chemotherapy and pharmacology</Title>
<ISOAbbreviation>Cancer Chemother. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.</ArticleTitle>
<Pagination><MedlinePgn>1175-1184</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Doxorubicin is a key component in many pediatric oncology treatment regimens; still pharmacology data on which current dosing regimens are based are very limited.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multinational pharmacokinetic study investigating age dependency of doxorubicin metabolism and elimination in children with cancer. One hundred and one patients treated with doxorubicin according to a cancer-specific national or European therapeutic trial were recruited. Doses of doxorubicin ranged from 10.4 to 57.7 mg/m(2). Blood samples for measurement of doxorubicin and its metabolite doxorubicinol were collected after two administrations, with five samples collected in children <3 years and eight in children ≥3 years. A population pharmacokinetic approach was used for analysis, including pharmacogenetic covariates. Natriuretic peptides and cardiac troponins were measured to evaluate their role as early indicators of cardiotoxicity.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Age dependence of doxorubicin clearance was demonstrated, with children less than 3 years having a statistically significant lower clearance (21.1 ± 5.8 l/h/m(2)) than older children (26.6 ± 6.7 l/h/m(2)) (p = 0.0004) after correcting for body surface area. No effect of the investigated genetic polymorphisms on the pharmacokinetics could be observed. Although natriuretic peptides were transiently elevated after each doxorubicin administration and troponin levels increased with increasing doxorubicin exposure, only limited correlation could be observed between their blood levels and doxorubicin pharmacokinetics.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the European framework of funding and regulatory support, an add-on study to existing therapeutic trials was developed. The pediatric need concerning missing PK data could be addressed with limited burden for the patients. Empirically used dose adaptations for infants were generally found to be justified based on our PK analyses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krischke</LastName>
<ForeName>Miriam</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Zentrum für Klinische Studien (ZKS), University Hospital Münster, Von-Esmarch-Straße 62, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hempel</LastName>
<ForeName>Georg</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Völler</LastName>
<ForeName>Swantje</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical and Medical Chemistry, Clinical Pharmacy, Westfälische Wilhelms-Universität Münster, Corrensstraße 48, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>André</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>INSERM UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Hematology and Pediatric Oncology Department, La Timone University Hospital of Marseille, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>D'Incalci</LastName>
<ForeName>Maurizio</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa, 19, 20156, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bisogno</LastName>
<ForeName>Gianni</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Dipartimento di Pediatria, Clinica di Oncoematologia, via Giustiniani, 3, 35100, Padua, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Köpcke</LastName>
<ForeName>Wolfgang</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Borowski</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Schmeddingstraße 56, 48149, Münster, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Herold</LastName>
<ForeName>Ralf</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>European Medicines Agency (EMA), 30 Churchill Place, Canary Wharf, London, E14 5EU, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Boddy</LastName>
<ForeName>Alan V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo><Affiliation>Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Faculty of Pharmacy, University of Sydney, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Boos</LastName>
<ForeName>Joachim</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Pediatric Hematology and Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. boosj@uni-muenster.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Cancer Chemother Pharmacol</MedlineTA>
<NlmUniqueID>7806519</NlmUniqueID>
<ISSNLinking>0344-5704</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014336">Troponin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63</RefSource>
<PMID Version="1">23314734</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 1;30(13):1422-8</RefSource>
<PMID Version="1">21900104</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2011 Dec;33(6):766-71</RefSource>
<PMID Version="1">22105595</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacokinet. 2015 Nov;54(11):1139-49</RefSource>
<PMID Version="1">25925711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Apr 1;30(10):1042-9</RefSource>
<PMID Version="1">22370326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Pharmacol. 2003 Feb;51(2):107-18</RefSource>
<PMID Version="1">12647011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Blood Cancer. 2008 Sep;51(3):327-33</RefSource>
<PMID Version="1">18523992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1991 Mar 21;324(12):808-15</RefSource>
<PMID Version="1">1997853</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Pediatr Oncol. 2002 May;38(5):329-37</RefSource>
<PMID Version="1">11979457</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 1991 Jun;37(6):845-52</RefSource>
<PMID Version="1">2049849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Chim Acta. 1996 Feb 9;245(1):19-38</RefSource>
<PMID Version="1">8646813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacokinet. 2015 Nov;54(11):1091-3</RefSource>
<PMID Version="1">26123706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cardiol Res Pract. 2011 Feb 10;2011:134679</RefSource>
<PMID Version="1">21331374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacokinet. 1988 Jul;15(1):15-31</RefSource>
<PMID Version="1">3042244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Blood Cancer. 2013 Aug;60(8):1375-81</RefSource>
<PMID Version="1">23441093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pediatr Hematol Oncol. 2008 Sep;25(7):655-64</RefSource>
<PMID Version="1">18850478</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1991 Mar;83(3):902-12</RefSource>
<PMID Version="1">1999039</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014336" MajorTopicYN="N">Troponin</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Cancer</Keyword>
<Keyword MajorTopicYN="Y">Cardiotoxicity</Keyword>
<Keyword MajorTopicYN="Y">Children</Keyword>
<Keyword MajorTopicYN="Y">Doxorubicin</Keyword>
<Keyword MajorTopicYN="Y">Pharmacokinetic</Keyword>
</KeywordList>
<CoiStatement>J. Boos served personally as a consultant and participated in advisory boards and safety boards for the medac GmbH. In addition, institutional grants and scientific co-operations with medac had been established. G. Hempel received research funding from medac GmbH and served as a speaker for medac GmbH. The other authors declare that they have no conflict of interest. Ethical standard All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent Informed consent was obtained from all individual participants included in the study.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>06</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>10</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>10</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>6</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>10</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27770238</ArticleId>
<ArticleId IdType="doi">10.1007/s00280-016-3174-8</ArticleId>
<ArticleId IdType="pii">10.1007/s00280-016-3174-8</ArticleId>
<ArticleId IdType="pmc">PMC5114325</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001422 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001422 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27770238
   |texte=   Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27770238" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki